Uphoff Eleonora, Ekers David, Robertson Lindsay, Dawson Sarah, Sanger Emily, South Emily, Samaan Zainab, Richards David, Meader Nicholas, Churchill Rachel
Cochrane Common Mental Disorders, University of York, York, UK.
Centre for Reviews and Dissemination, University of York, York, UK.
Cochrane Database Syst Rev. 2020 Jul 6;7(7):CD013305. doi: 10.1002/14651858.CD013305.pub2.
Behavioural activation is a brief psychotherapeutic approach that seeks to change the way a person interacts with their environment. Behavioural activation is increasingly receiving attention as a potentially cost-effective intervention for depression, which may require less resources and may be easier to deliver and implement than other types of psychotherapy.
To examine the effects of behavioural activation compared with other psychological therapies for depression in adults. To examine the effects of behavioural activation compared with medication for depression in adults. To examine the effects of behavioural activation compared with treatment as usual/waiting list/placebo no treatment for depression in adults.
We searched CCMD-CTR (all available years), CENTRAL (current issue), Ovid MEDLINE (1946 onwards), Ovid EMBASE (1980 onwards), and Ovid PsycINFO (1806 onwards) on the 17 January 2020 to identify randomised controlled trials (RCTs) of 'behavioural activation', or the main elements of behavioural activation for depression in participants with clinically diagnosed depression or subthreshold depression. We did not apply any restrictions on date, language or publication status to the searches. We searched international trials registries via the World Health Organization's trials portal (ICTRP) and ClinicalTrials.gov to identify unpublished or ongoing trials.
We included randomised controlled trials (RCTs) of behavioural activation for the treatment of depression or symptoms of depression in adults aged 18 or over. We excluded RCTs conducted in inpatient settings and with trial participants selected because of a physical comorbidity. Studies were included regardless of reported outcomes.
Two review authors independently screened all titles/abstracts and full-text manuscripts for inclusion. Data extraction and 'Risk of bias' assessments were also performed by two review authors in duplicate. Where necessary, we contacted study authors for more information.
Fifty-three studies with 5495 participants were included; 51 parallel group RCTs and two cluster-RCTs. We found moderate-certainty evidence that behavioural activation had greater short-term efficacy than treatment as usual (risk ratio (RR) 1.40, 95% confidence interval (CI) 1.10 to 1.78; 7 RCTs, 1533 participants), although this difference was no longer evident in sensitivity analyses using a worst-case or intention-to-treat scenario. Compared with waiting list, behavioural activation may be more effective, but there were fewer data in this comparison and evidence was of low certainty (RR 2.14, 95% CI 0.90 to 5.09; 1 RCT, 26 participants). No evidence on treatment efficacy was available for behavioural activation versus placebo and behavioural activation versus no treatment. We found moderate-certainty evidence suggesting no evidence of a difference in short-term treatment efficacy between behavioural activation and CBT (RR 0.99, 95% CI 0.92 to 1.07; 5 RCTs, 601 participants). Fewer data were available for other comparators. No evidence of a difference in short term-efficacy was found between behavioural activation and third-wave CBT (RR 1.10, 95% CI 0.91 to 1.33; 2 RCTs, 98 participants; low certainty), and psychodynamic therapy (RR 1.21, 95% CI 0.74 to 1.99; 1 RCT,60 participants; very low certainty). Behavioural activation was more effective than humanistic therapy (RR 1.84, 95% CI 1.15 to 2.95; 2 RCTs, 46 participants; low certainty) and medication (RR 1.77, 95% CI 1.14 to 2.76; 1 RCT; 141 participants; moderate certainty), but both of these results were based on a small number of trials and participants. No evidence on treatment efficacy was available for comparisons between behavioural activation versus interpersonal, cognitive analytic, and integrative therapies. There was moderate-certainty evidence that behavioural activation might have lower treatment acceptability (based on dropout rate) than treatment as usual in the short term, although the data did not confirm a difference and results lacked precision (RR 1.64, 95% CI 0.81 to 3.31; 14 RCTs, 2518 participants). Moderate-certainty evidence did not suggest any difference in short-term acceptability between behavioural activation and waiting list (RR 1.17, 95% CI 0.70 to 1.93; 8 RCTs. 359 participants), no treatment (RR 0.97, 95% CI 0.45 to 2.09; 3 RCTs, 187 participants), medication (RR 0.52, 95% CI 0.23 to 1.16; 2 RCTs, 243 participants), or placebo (RR 0.72, 95% CI 0.31 to 1.67; 1 RCT; 96 participants; low-certainty evidence). No evidence on treatment acceptability was available comparing behavioural activation versus psychodynamic therapy. Low-certainty evidence did not show a difference in short-term treatment acceptability (dropout rate) between behavioural activation and CBT (RR 1.03, 95% CI 0.85 to 1.25; 12 RCTs, 1195 participants), third-wave CBT (RR 0.84, 95% CI 0.33 to 2.10; 3 RCTs, 147 participants); humanistic therapy (RR 1.06, 95% CI 0.20 to 5.55; 2 RCTs, 96 participants) (very low certainty), and interpersonal, cognitive analytic, and integrative therapy (RR 0.84, 95% CI 0.32 to 2.20; 4 RCTs, 123 participants). Results from medium- and long-term primary outcomes, secondary outcomes, subgroup analyses, and sensitivity analyses are summarised in the text.
AUTHORS' CONCLUSIONS: This systematic review suggests that behavioural activation may be more effective than humanistic therapy, medication, and treatment as usual, and that it may be no less effective than CBT, psychodynamic therapy, or being placed on a waiting list. However, our confidence in these findings is limited due to concerns about the certainty of the evidence. We found no evidence of a difference in short-term treatment acceptability (based on dropouts) between behavioural activation and most comparison groups (CBT, humanistic therapy, waiting list, placebo, medication, no treatment or treatment as usual). Again, our confidence in all these findings is limited due to concerns about the certainty of the evidence. No data were available about the efficacy of behaioural activation compared with placebo, or about treatment acceptability comparing behavioural activation and psychodynamic therapy, interpersonal, cognitive analytic and integrative therapies. The evidence could be strengthened by better reporting and better quality RCTs of behavioural activation and by assessing working mechanisms of behavioural activation.
行为激活是一种短期心理治疗方法,旨在改变个体与环境互动的方式。作为一种治疗抑郁症的潜在性价比高的干预措施,行为激活越来越受到关注,它可能比其他类型的心理治疗需要更少的资源,并且更易于实施。
比较行为激活与其他心理疗法对成人抑郁症的疗效。比较行为激活与药物治疗对成人抑郁症的疗效。比较行为激活与常规治疗/等待列表/安慰剂对照不治疗对成人抑郁症的疗效。
2020年1月17日,我们检索了中国临床试验注册中心(所有可用年份)、Cochrane系统评价数据库(当前期)、Ovid MEDLINE(1946年起)、Ovid EMBASE(1980年起)和Ovid PsycINFO(1806年起),以识别关于“行为激活”或行为激活主要元素治疗临床诊断抑郁症或亚阈值抑郁症患者的随机对照试验(RCT)。我们对检索没有设置日期、语言或发表状态的限制。我们通过世界卫生组织的试验平台(ICTRP)和ClinicalTrials.gov检索国际试验注册库,以识别未发表或正在进行的试验。
我们纳入了18岁及以上成年人行为激活治疗抑郁症或抑郁症状的随机对照试验(RCT)。我们排除了在住院环境中进行的RCT以及因身体合并症而入选的试验参与者。无论报告的结果如何,研究均被纳入。
两位综述作者独立筛选所有标题/摘要和全文手稿以确定是否纳入。数据提取和“偏倚风险”评估也由两位综述作者重复进行。必要时,我们联系研究作者以获取更多信息。
纳入了53项研究,共5495名参与者;51项平行组RCT和2项整群RCT。我们发现中等确定性证据表明,行为激活在短期疗效上优于常规治疗(风险比(RR)1.40,95%置信区间(CI)1.10至1.78;7项RCT,1533名参与者),尽管在使用最坏情况或意向性分析的敏感性分析中,这种差异不再明显。与等待列表相比,行为激活可能更有效,但此比较中的数据较少,证据确定性较低(RR 2.14,95%CI 0.90至5.09;1项RCT,26名参与者)。没有关于行为激活与安慰剂以及行为激活与不治疗比较的治疗疗效证据。我们发现中等确定性证据表明,行为激活与认知行为疗法(CBT)在短期治疗疗效上没有差异(RR 0.99,95%CI 0.92至1.07;5项RCT,601名参与者)。其他比较组的数据较少。行为激活与第三波CBT(RR 1.10,95%CI 0.91至1.33;2项RCT,98名参与者;低确定性)以及心理动力疗法(RR 1.21,95%CI 0.74至1.99;1项RCT,60名参与者;非常低确定性)在短期疗效上没有差异的证据。行为激活比人本主义疗法(RR 1.84,95%CI 1.15至2.95;2项RCT,46名参与者;低确定性)和药物治疗(RR 1.77,95%CI 1.14至2.76;1项RCT,141名参与者;中等确定性)更有效,但这两个结果均基于少量试验和参与者。行为激活与人际治疗、认知分析治疗和综合治疗比较的治疗疗效没有证据。有中等确定性证据表明,行为激活在短期内的治疗可接受性(基于脱落率)可能低于常规治疗,尽管数据未证实存在差异且结果缺乏精确性(RR 1.64,95%CI 0.81至3.31;14项RCT,2518名参与者)。中等确定性证据未表明行为激活与等待列表(RR 1.17,95%CI 0.70至1.93;8项RCT,359名参与者)、不治疗(RR 0.97,95%CI 0.45至2.09;3项RCT,187名参与者)、药物治疗(RR 0.52,95%CI 0.23至1.16;2项RCT,243名参与者)或安慰剂(RR 0.72,95%CI 0.31至1.67;1项RCT,96名参与者;低确定性证据)在短期可接受性上存在差异。行为激活与心理动力疗法比较的治疗可接受性没有证据。低确定性证据未显示行为激活与CBT(RR 1.03,95%CI 0.85至1.25;12项RCT,1195名参与者)、第三波CBT(RR 0.84,95%CI 0.33至2.10;3项RCT,147名参与者)、人本主义疗法(RR 1.06,95%CI 0.20至5.55;2项RCT,96名参与者)(非常低确定性)以及人际治疗、认知分析治疗和综合治疗(RR 0.84,95%CI 0.32至2.20;4项RCT,123名参与者)在短期治疗可接受性(脱落率)上存在差异。中长期主要结局、次要结局、亚组分析和敏感性分析的结果在正文中进行了总结。
本系统评价表明,行为激活可能比人本主义疗法、药物治疗和常规治疗更有效,并且可能与CBT、心理动力疗法或等待列表治疗效果相当。然而,由于对证据确定性的担忧,我们对这些发现的信心有限。我们发现行为激活与大多数比较组(CBT、人本主义疗法、等待列表、安慰剂、药物治疗、不治疗或常规治疗)在短期治疗可接受性(基于脱落率)上没有差异的证据。同样,由于对证据确定性的担忧,我们对所有这些发现的信心有限。没有关于行为激活与安慰剂比较的疗效数据,也没有关于行为激活与心理动力疗法、人际治疗、认知分析治疗和综合治疗比较的治疗可接受性数据。通过更好地报告行为激活以及开展更高质量的RCT,并评估行为激活的作用机制,可以加强证据。